APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Therapeutics

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Selected research

Market Analysis & Forecast

Global Peptide Therapeutics Market Analysis and Forecast 2026-2032

26 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide Therapeutics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Therapeutics Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Therapeutics Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%.

North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent.

Read the full market overview

In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.

Report Includes

This report presents an overview of global market for Peptide Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptide Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Peptide Therapeutics Segment by Company

Sanofi

Teva

Novo Nordisk

Takeda

Eli Lilly

AstraZeneca

Novartis

AbbVie

Ipsen

Ferring

Merck

The Medicines

J & J

Peptide Therapeutics Segment by Type

Injection

Oral

Other

Peptide Therapeutics Segment by Application

Cancer

Metabolic Disorders

Central Nervous System

Other

Peptide Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptide Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptide Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Player Table 3. Oral Major Player Table 4. Other Major Player Table 5. Global Peptide Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Major Player Table 7. Metabolic Disorders Major Player Table 8. Central Nervous System Major Player Table 9. Other Major Player Table 10. Peptide Therapeutics Industry Trends Table 11. Peptide Therapeutics Industry Drivers Table 12. Peptide Therapeutics Industry Opportunities and Challenges Table 13. Peptide Therapeutics Industry Restraints Table 14. Global Peptide Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Peptide Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Peptide Therapeutics Market Share by Region (2021-2026) Table 17. Global Peptide Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Peptide Therapeutics Market Share by Region (2027-2032) Table 19. Global Peptide Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Peptide Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Peptide Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Peptide Therapeutics Key Players Headquarters & Area Served Table 23. Global Peptide Therapeutics Players, Product Type & Application Table 24. Global Peptide Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Peptide Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Peptide Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Peptide Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Peptide Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Peptide Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Peptide Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Peptide Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Sanofi Company Information Table 38. Sanofi Business Overview Table 39. Sanofi Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Sanofi Peptide Therapeutics Product Portfolio Table 41. Sanofi Recent Development Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Peptide Therapeutics Product Portfolio Table 46. Teva Recent Development Table 47. Novo Nordisk Company Information Table 48. Novo Nordisk Business Overview Table 49. Novo Nordisk Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Novo Nordisk Peptide Therapeutics Product Portfolio Table 51. Novo Nordisk Recent Development Table 52. Takeda Company Information Table 53. Takeda Business Overview Table 54. Takeda Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Takeda Peptide Therapeutics Product Portfolio Table 56. Takeda Recent Development Table 57. Eli Lilly Company Information Table 58. Eli Lilly Business Overview Table 59. Eli Lilly Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Eli Lilly Peptide Therapeutics Product Portfolio Table 61. Eli Lilly Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. AstraZeneca Peptide Therapeutics Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Novartis Peptide Therapeutics Product Portfolio Table 71. Novartis Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. AbbVie Peptide Therapeutics Product Portfolio Table 76. AbbVie Recent Development Table 77. Ipsen Company Information Table 78. Ipsen Business Overview Table 79. Ipsen Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Ipsen Peptide Therapeutics Product Portfolio Table 81. Ipsen Recent Development Table 82. Ferring Company Information Table 83. Ferring Business Overview Table 84. Ferring Peptide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Ferring Peptide Therapeutics Product Portfolio Table 86. Ferring Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck Peptide Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Merck Peptide Therapeutics Product Portfolio Table 91. Merck Recent Development Table 92. The Medicines Company Information Table 93. The Medicines Business Overview Table 94. The Medicines Peptide Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. The Medicines Peptide Therapeutics Product Portfolio Table 96. The Medicines Recent Development Table 97. J & J Company Information Table 98. J & J Business Overview Table 99. J & J Peptide Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. J & J Peptide Therapeutics Product Portfolio Table 101. J & J Recent Development Table 102. North America Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Peptide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Peptide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Peptide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Peptide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 116. China Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 117. China Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 118. China Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 119. China Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Peptide Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Peptide Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Peptide Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Peptide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Peptide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Peptide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Peptide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Peptide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Peptide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Peptide Therapeutics Image Figure 2. Global Peptide Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Other Image Figure 7. Global Peptide Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Peptide Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Image Figure 10. Metabolic Disorders Image Figure 11. Central Nervous System Image Figure 12. Other Image Figure 13. Global Peptide Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Peptide Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peptide Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Peptide Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peptide Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peptide Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Peptide Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Peptide Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Peptide Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Peptide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Peptide Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Peptide Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Peptide Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Peptide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Peptide Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Peptide Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Peptide Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Peptide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Peptide Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Peptide Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Peptide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Peptide Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Peptide Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Peptide Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Peptide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Peptide Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Peptide Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Peptide Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Peptide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other
Companies covered
  • Sanofi
  • Teva
  • Novo Nordisk
  • Takeda
  • Eli Lilly
  • AstraZeneca
  • Novartis
  • AbbVie
  • Ipsen
  • Ferring
  • Merck
  • The Medicines
  • J & J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide Therapeutics Market by Type
  3. 1.2.1 Global Peptide Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.2.4 Other
  7. 1.3 Peptide Therapeutics Market by Application
  8. 1.3.1 Global Peptide Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Metabolic Disorders
  11. 1.3.4 Central Nervous System
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peptide Therapeutics Market Dynamics
  1. 2.1 Peptide Therapeutics Industry Trends
  2. 2.2 Peptide Therapeutics Industry Drivers
  3. 2.3 Peptide Therapeutics Industry Opportunities and Challenges
  4. 2.4 Peptide Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptide Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Peptide Therapeutics Growth Trends by Region
  3. 3.2.1 Global Peptide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptide Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptide Therapeutics Revenue by Players
  2. 4.1.1 Global Peptide Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptide Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptide Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptide Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Peptide Therapeutics Players, Product Type & Application
  8. 4.5 Global Peptide Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptide Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Peptide Therapeutics Tier 1, Tier 2, and Tier 3
5 Peptide Therapeutics Market Size by Type
  1. 5.1 Global Peptide Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Peptide Therapeutics Revenue Market Share by Type (2021-2032)
6 Peptide Therapeutics Market Size by Application
  1. 6.1 Global Peptide Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptide Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Peptide Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Peptide Therapeutics Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Peptide Therapeutics Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Novo Nordisk
  14. 7.3.1 Novo Nordisk Company Information
  15. 7.3.2 Novo Nordisk Business Overview
  16. 7.3.3 Novo Nordisk Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novo Nordisk Peptide Therapeutics Product Portfolio
  18. 7.3.5 Novo Nordisk Recent Developments
  19. 7.4 Takeda
  20. 7.4.1 Takeda Company Information
  21. 7.4.2 Takeda Business Overview
  22. 7.4.3 Takeda Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Takeda Peptide Therapeutics Product Portfolio
  24. 7.4.5 Takeda Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Peptide Therapeutics Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Peptide Therapeutics Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Peptide Therapeutics Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 AbbVie
  44. 7.8.1 AbbVie Company Information
  45. 7.8.2 AbbVie Business Overview
  46. 7.8.3 AbbVie Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Peptide Therapeutics Product Portfolio
  48. 7.8.5 AbbVie Recent Developments
  49. 7.9 Ipsen
  50. 7.9.1 Ipsen Company Information
  51. 7.9.2 Ipsen Business Overview
  52. 7.9.3 Ipsen Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ipsen Peptide Therapeutics Product Portfolio
  54. 7.9.5 Ipsen Recent Developments
  55. 7.10 Ferring
  56. 7.10.1 Ferring Company Information
  57. 7.10.2 Ferring Business Overview
  58. 7.10.3 Ferring Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Ferring Peptide Therapeutics Product Portfolio
  60. 7.10.5 Ferring Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Merck Peptide Therapeutics Product Portfolio
  66. 7.11.5 Merck Recent Developments
  67. 7.12 The Medicines
  68. 7.12.1 The Medicines Company Information
  69. 7.12.2 The Medicines Business Overview
  70. 7.12.3 The Medicines Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 The Medicines Peptide Therapeutics Product Portfolio
  72. 7.12.5 The Medicines Recent Developments
  73. 7.13 J & J
  74. 7.13.1 J & J Company Information
  75. 7.13.2 J & J Business Overview
  76. 7.13.3 J & J Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  77. 7.13.4 J & J Peptide Therapeutics Product Portfolio
  78. 7.13.5 J & J Recent Developments
8 North America
  1. 8.1 North America Peptide Therapeutics Revenue (2021-2032)
  2. 8.2 North America Peptide Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptide Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptide Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Peptide Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptide Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptide Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptide Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Peptide Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptide Therapeutics Revenue by Country
  11. 8.6.1 North America Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptide Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptide Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peptide Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Peptide Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptide Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptide Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Peptide Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptide Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptide Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptide Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Peptide Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptide Therapeutics Revenue by Country
  11. 9.6.1 Europe Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptide Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptide Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peptide Therapeutics Revenue (2021-2032)
  2. 10.2 China Peptide Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Peptide Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Peptide Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Peptide Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Peptide Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Peptide Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Peptide Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Peptide Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Peptide Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptide Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptide Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Peptide Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptide Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptide Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptide Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Peptide Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptide Therapeutics Revenue by Country
  11. 11.6.1 Asia Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptide Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptide Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Peptide Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptide Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptide Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptide Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptide Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptide Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptide Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptide Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptide Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Peptide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptide Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptide Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst